For prostate cancer, a study from Poland confirmed BARD1 mutation carriers were not at elevated risk of prostate cancer [48]; however, another study of 9185 men with aggressive prostate cancer from 18 international studies provided evidence of greater risk (OR ≥ 2) but the carrier frequency differences between aggressive and non-aggressive prostate cancer were not statistically significant [49]. The gene discussed is BARD1; the disease is prostate carcinoma.